Drug repurposing in pancreatic ductal adenocarcinoma

Información del proyecto

REPANCAN

Identificador del acuerdo de subvención: 891135

DOI 10.3030/891135

Proyecto cerrado

Fecha de la firma de la CE 24 Marzo 2020

Fecha de inicio 1 Julio 2020

Fecha de finalización 30 Junio 2022

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total € 140 021,76

Aportación de la UE € 140 021,76

Coordinado por

INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE
Serbia

Publicaciones

Conference proceedings (11)

Potential anti-metastatic activity of Imidazoline I1 receptor agonists in pancreatic ductal adenocarcinoma.

Autores: Zivic K, Pavlovic M, Ostojic M, Srdic-Rajic T, Grahovac J.
Publicado en: Keystone Symposium “Precision Oncology: Translating Discovery to the Clinic”., 2021
Editor: Keystone Symposia

Imidazoline-1 receptor agonist reduces cytokine production of PDAC stellate cells

Autores: Živić K, Ostojić M , Pavlović M, Srdić-Rajić T, Grahovac J.
Publicado en: EACR2022 Annual congress abstract book, 2022
Editor: EACR

Nischarin agonist rilmenidine inhibits pancreatic ductal adenocarcinoma cell migration and invasion

Autores: Marijana Pavlovic, Marija Ostojic, Kristina Zivic, Aleksandar Pavic, Tatjana Srdic-Rajic, Jelena Grahovac
Publicado en: Cancer Research, Edición Volume 82 12_Supplement, 2022, Página(s) 3463-3463
Editor: The American Association for Cancer Research
DOI: 10.1158/1538-7445.am2022-3463

Rilmenidine binds to and inhibits the activity of MDR pumps in pancreatic ductal adenocarcinoma

Autores: Ostojić M, Đurić A, Srdić-Rajić T, Dobričić V, Grahovac J.
Publicado en: 5th Annual meeting of the CA17104 Abstract book, 2022
Editor: University of Coimbra

Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing

Autores: Jelena Grahovac, Marijana Pavlovic, Marija Ostojic, Kristina Zivic, Daniel Galun and Tatjana Srdic-Rajic
Publicado en: Cancer Research, Edición Volume 81 22_Supplement, 2021
Editor: American Association for Cancer Research
DOI: 10.1158/1538-7445.panca21-po-040

Anti-migratory properties of Nischarin agonist rilmenidine in pancreatic ductal adenocarcinoma.

Autores: Živić K, Ostojić M, Pavlović M, Srdić-Rajić T, Grahovac J.
Publicado en: Proceedings of the Tenth Conference of the Serbian Biochemical Society, 2021, Página(s) 192
Editor: Faculty of Chemistry, University of BElgrade

Nischarin as a target for drug repurposing in solid tumors.

Autores: Ostojic M, Pavlovic M, Zivic K, Srdic-Rajic T, Grahovac J
Publicado en: EACR2021 conference proceedings, 2021
Editor: EACR

I1 imidazoline receptor ligand inhibits P-glycoprotein efflux in pancreatic ductal adenocarcinoma cells

Autores: Ostojić M, Srdić-Rajić T, Pavlović M, Živić K, Grahovac J.
Publicado en: 5th Congress of SDIR: Translational potential of cancer research in Serbia Abstract book, 2021
Editor: SDIR

Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing

Autores: Jelena Grahovac
Publicado en: 5th annual meeting of the COST-1704 Abstract book, 2021
Editor: STRATAGEM

Drug repurposing in pancreatic ductal adenocarcinoma

Autores: Jelena Grahovac
Publicado en: 5th Congress of SDIR: Translational potential of cancer research in Serbia Abstract book, 2021, Página(s) p6
Editor: SDIR

Potential anti-MDR effect of rilmenidine in pancreatic ductal adenocarcinoma.

Autores: Ostojić M, Srdić-Rajić T, Pavlović M, Živić K, Grahovac J
Publicado en: EACR Conference Goodbye Flat Biology: Next Generation Cancer Models Abstract book, 2021
Editor: EACR

Other (1)

Nischarin expression may have differing roles in male and female melanoma patients

Autores: Marija Ostojić, Marko Jevrić, Olivera Mitrović-Ajtić, Miljana Tanić, Milena Čavić, Tatjana Srdić-Rajić Jelena Grahovac
Publicado en: Research Square, 2022
Editor: Research Square
DOI: 10.21203/rs.3.rs-1576440/v2